Lentivirus

Lentivirus
Name	Lentivirus
Virus group	Group VI (ssRNA-RT viruses)
Family	Retroviridae
Diseases	Human immunodeficiency virus disease, equine infectious anemia, caprine arthritis encephalitis
Hosts	Humans, non-human primates, horses, sheep, goats

Lentivirus is a genus of slow-progressing retroviruses that infect vertebrate hosts and cause persistent, often chronic diseases. First characterized through work on Human immunodeficiency virus and veterinary pathogens, lentiviruses are notable for long incubation periods, integration into host genomes, and capacity to evade immune responses. Research on lentiviruses intersects with investigations led by institutions such as Pasteur Institute, Centers for Disease Control and Prevention, and National Institutes of Health.

Taxonomy and classification

Lentiviruses belong to the family Retroviridae and are classified within the subfamily Orthoretrovirinae. Taxonomic revisions driven by researchers at organizations like the International Committee on Taxonomy of Viruses and studies from laboratories at University of Oxford and Harvard University differentiate species infecting humans, non-human primates, equids, ovines, caprines, and felids. Notable members include Human immunodeficiency virus type 1, Human immunodeficiency virus type 2, Simian immunodeficiency virus, Equine infectious anemia virus, Caprine arthritis encephalitis virus, and Feline immunodeficiency virus. Classification uses phylogenetic analyses developed in groups at Max Planck Society and sequencing centers such as Wellcome Sanger Institute.

Virology and structure

Lentiviruses are enveloped, roughly 80–100 nm diameter particles with an icosahedral capsid core; structural studies at Cold Spring Harbor Laboratory and EMBL elucidated capsid and envelope architecture. The virion envelope contains glycoproteins derived from the host cell membrane and viral Env polyprotein, with notable interactions studied by teams at Massachusetts Institute of Technology and Stanford University. Internal proteins include Gag-derived matrix, capsid, and nucleocapsid components; enzymatic proteins—reverse transcriptase, integrase, and protease—are products of the Pol polyprotein. Host cell receptors and coreceptors such as CD4 and CCR5 were characterized in collaborations involving University of California, San Francisco and The Scripps Research Institute.

Genome and replication cycle

The lentiviral genome is a single-stranded, positive-sense RNA of ~7–12 kilobases with long terminal repeats (LTRs) flanking coding regions. Genomic organization includes gag, pol, env and accessory/regulatory genes (for example, nef, vif, vpr, vpu/vpx) revealed in landmark studies from Imperial College London and Johns Hopkins University. After attachment and fusion mediated by viral Env and host receptors studied by Rockefeller University investigators, reverse transcription yields a DNA provirus that integrates into host chromosomal DNA via integrase activity characterized by groups at Cold Spring Harbor Laboratory. Proviral latency, transcriptional control by host factors (for example, NF-κB, SP1) and regulation by viral Tat and Rev proteins were elucidated in research at University of Cambridge and Yale University. Assembly, budding, and maturation processes involving host ESCRT machinery were described in work from Biozentrum Basel and Duke University.

Pathogenesis and clinical manifestations

Lentiviral infections produce chronic pathology with tissue tropisms varying by species. Human infections with Human immunodeficiency virus type 1 and Human immunodeficiency virus type 2 cause progressive immune deficiency leading to opportunistic infections and malignancies documented in cohorts by World Health Organization and clinical centers like Johns Hopkins Hospital. Simian infections such as Simian immunodeficiency virus inform pathogenic mechanisms via primate studies at Yerkes National Primate Research Center. Equine infections (caused by Equine infectious anemia virus) produce anemia, fever, and weight loss monitored by veterinary services at United States Department of Agriculture and Royal Veterinary College. Caprine and ovine lentiviruses cause arthritis, encephalitis, and mastitis described in research from Cornell University and INRAE.

Transmission and epidemiology

Transmission routes vary: human lentiviruses spread through sexual contact, blood exposure, and perinatal routes documented in public health studies by UNAIDS and Centers for Disease Control and Prevention; simian lentiviruses transmit by bites and vertical routes in field studies from Primate Research Centers; equine and ruminant lentiviruses spread via blood-feeding insects, iatrogenic exposures, and colostrum analyzed by veterinary epidemiologists at University of Glasgow and University of Melbourne. Global epidemiology of human lentiviruses has been mapped by consortia including Joint United Nations Programme on HIV/AIDS and sequencing initiatives at Broad Institute.

Laboratory diagnosis and detection

Diagnosis relies on serology, nucleic acid amplification, and viral culture. Enzyme-linked immunosorbent assays and western blot confirmations were standardized by laboratories at Food and Drug Administration and Public Health England. Nucleic acid tests (PCR, RT-PCR, quantitative viral load assays) developed at Roche Diagnostics and academic centers like Karolinska Institutet permit detection and monitoring. Point-of-care rapid tests used in clinics such as Médecins Sans Frontières settings enable screening; viral sequencing for resistance and phylogenetics is performed in reference labs including Los Alamos National Laboratory and Genome Institute at Washington University.

Use in research and gene therapy

Lentiviral vectors, engineered to be replication-incompetent, are powerful tools for stable gene transfer in mammalian systems developed through collaborations involving Addgene, Novartis, and academic groups at University of Pennsylvania and Institut Pasteur. Clinical applications include chimeric antigen receptor T cell therapies pioneered at Memorial Sloan Kettering Cancer Center and ex vivo gene therapies for immunodeficiencies and hematologic disorders evaluated in trials at St. Jude Children’s Research Hospital and Karolinska University Hospital. Safety concerns—insertional mutagenesis, replication-competent recombinants—are addressed by regulatory guidance from European Medicines Agency and Food and Drug Administration and by vector design improvements from labs at Salk Institute and Fred Hutchinson Cancer Center.

Category:Viruses